Physician profile
Lawrence Weiss
NPI 1356308159
$215,078.19
in general payments reported to CMS, 2019-2025
16 companies · $2,435 in 2025
The $2,435 reported for 2025 was more than what 80% of Anatomic Pathology providers received nationally (typical 2025 total: $110).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $69K · 2020: $11K · 2021: $64K · 2022: $32K · 2023: $29K · 2024: $8,532 · 2025: $2,435.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $23K · Honoraria: $8,000 · Travel and Lodging: $6,110 · Consulting Fee: $1,860 · Food and Beverage: $919.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $22,643.21 |
| Honoraria | $8,000.00 |
| Travel and Lodging | $6,110.22 |
| Consulting Fee | $1,860.00 |
| Food and Beverage | $918.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $53,195.30 | 2019-2023 | Keytruda |
| Roche Diagnostics Corporation | $49,210.00 | 2021-2022 | |
| Genentech USA, INC. | $45,612.38 | 2019-2023 | |
| Agilent Technologies, INC. | $21,158.94 | 2023-2024 | Pd-L1 Ihc 28-8 Pharmdx |
| Bayer Healthcare Pharmaceuticals INC. | $19,061.34 | 2019-2020 | |
| Genzyme Corporation | $6,709.97 | 2022 | |
| Ventana Medical Systems, INC. | $6,500.00 | 2021 | |
| Novartis Pharmaceuticals Corporation | $6,195.99 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $2,512.48 | 2024-2025 | Truqap |
| Takeda Pharmaceuticals U.S.A., INC. | $1,680.00 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $1,557.50 | 2021 | |
| Eli Lilly and Company | $1,475.00 | 2019 | |
| Stemline Therapeutics INC. | $104.07 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $59.26 | 2022 | |
| Inspire Medical Systems, INC. | $24.85 | 2025 | Inspire |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $21.11 | 2023 | Ayvakit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Weiss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.